Form 4: Cellectar Biosciences Director, John Neis, Acquires Stock Options

Director John Neis acquired stock options in Cellectar Biosciences, Inc. on February 14, 2025.

Summary

• On February 14, 2025, John Neis, a director of Cellectar Biosciences, Inc., acquired stock options to purchase 60,000 shares of common stock at an exercise price of $0.29 per share.
• The options vest fully on February 14, 2026, contingent upon continued service.
• Following the transaction, Neis directly owns 60,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider ownership can be a positive signal, this is a routine grant.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

stock options, director, Cellectar Biosciences, CLRB, Form 4, beneficial ownership, John Neis